Loading
A phase 2 trial of epirubicin, cyclophosphamide, paclitaxel / nab-paclitaxel and carboplatin in triple-negative breast cancer, run by University College Hospital, Ibadan, now recruiting.
MicroRNA Profiles in Triple Negative Breast Cancer is a phase 2, interventional study registered as NCT04771871 by University College Hospital, Ibadan, with a registry enrolment figure of 42 participants, started 2021-11-29 and due to reach its primary completion in 2027-03. Interventions recorded: Epirubicin; Cyclophosphamide; Paclitaxel; Carboplatin. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Patients with histologically confirmed carcinoma of the female breast with triple negative status by immuno-histochemistry (IHC)". Sites: Nigeria. No results are recorded here; the registry entry is the source.
Shares Epirubicin, Cyclophosphamide, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Epirubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents and the tag tnbc-deep-dive.
Shares Epirubicin, Cyclophosphamide, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Cyclophosphamide, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents and the tag tnbc-deep-dive.
Shares Epirubicin, Cyclophosphamide, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Epirubicin, Cyclophosphamide, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Epirubicin, Cyclophosphamide, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Epirubicin, Cyclophosphamide, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.